Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
10.44
-0.10 (-0.95%)
At close: Oct 30, 2026, 4:00 PM EDT
10.72
+0.28 (2.67%)
After-hours: Oct 30, 2026, 7:59 PM EDT
Puma Biotechnology Employees
Puma Biotechnology had 179 employees as of December 31, 2025. The number of employees increased by 7 or 4.07% compared to the previous year. That makes Puma Biotechnology the 27,675th largest employer in the world and 3,486th in the United States.
Employees
179
Change (1Y)
7
Growth (1Y)
4.07%
Revenue / Employee
$1,291,866
Profits / Employee
$149,263
Market Cap
538.91M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 179 | 7 | 4.07% |
| Dec 31, 2024 | 172 | -13 | -7.03% |
| Dec 31, 2023 | 185 | -7 | -3.65% |
| Dec 31, 2022 | 192 | -4 | -2.04% |
| Dec 31, 2021 | 196 | -71 | -26.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Valneva SE | 620 |
| Arvinas | 246 |
| Oculis Holding AG | 60 |
| Surrozen | 44 |
| Shattuck Labs | 40 |
| DiaMedica Therapeutics | 35 |
| Bright Minds Biosciences | 26 |
PBYI News
- 8 days ago - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results - Business Wire
- 25 days ago - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Puma Biotechnology starts Phase 2 study of alisertib in small cell lung cancer - TheFly
- 6 weeks ago - Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Puma Biotechnology Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference - Business Wire
- 1 month ago - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Puma Biotechnology price target raised to $6 from $5 at TD Cowen - TheFly